{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040318","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.631050+00:00","generated_at":"2026-06-08T05:49:04.617009+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Abeona submits BLA for pz-cel; Q3 net loss $11.8M, cash $54.1M","bullets":["Q3 net loss $11.8M ($0.48/share) vs $6.4M ($1.00/share) in Q3 2022.","Cash and short-term investments $54.1M; estimated runway into Q4 2024.","BLA for pz-cel (gene therapy for RDEB) submitted in September; FDA decision expected late-Nov 2023.","Raised $25M in July registered direct offering; commercial launch prep underway.","Appointed Madhav Vasanthavada as Chief Commercial Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040318","json":"https://secwatch.observer/filing/0001493152-23-040318.json","markdown":"https://secwatch.observer/filing/0001493152-23-040318.md","text":"https://secwatch.observer/filing/0001493152-23-040318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315223040318/0001493152-23-040318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315223040318/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:49:04.617009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"707bc294ee6cc194a47df982051668675d424f10","claim":"ABEONA THERAPEUTICS INC. reported the third quarter of 2023 results: net income Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common s, EPS $0.48 loss per common share.","evidence_excerpt":"Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common share as compared to a net loss attributable to common shareholders of $6.4 million, or $1.00 loss per common share, in the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223040318/0001493152-23-040318-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Net income","value":"Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common s"},{"label":"EPS","value":"$0.48 loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}